Market Research Logo

Spinal Cord Injury - Pipeline Review, H1 2015

Spinal Cord Injury - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Spinal Cord Injury - Pipeline Review, H1 2015’, provides an overview of the Spinal Cord Injury’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Spinal Cord Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Cord Injury and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Spinal Cord Injury
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Spinal Cord Injury and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Spinal Cord Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Spinal Cord Injury pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Spinal Cord Injury
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Spinal Cord Injury pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Spinal Cord Injury Overview
Therapeutics Development
Pipeline Products for Spinal Cord Injury - Overview
Pipeline Products for Spinal Cord Injury - Comparative Analysis
Spinal Cord Injury - Therapeutics under Development by Companies
Spinal Cord Injury - Therapeutics under Investigation by Universities/Institutes
Spinal Cord Injury - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Spinal Cord Injury - Products under Development by Companies
Spinal Cord Injury - Products under Investigation by Universities/Institutes
Spinal Cord Injury - Companies Involved in Therapeutics Development
Acorda Therapeutics, Inc.
Asubio Pharma Co., Ltd.
Athersys, Inc.
Axerion Therapeutics, Inc.
BioArctic Neuroscience AB
Faron Pharmaceuticals Oy
FirstString Research, Inc.
Genervon Biopharmaceuticals, LLC
Grupo Ferrer Internacional, S.A.
Hemostemix Ltd
Histocell S.L.
Intellipharmaceutics International Inc.
K-Stemcell Co., Ltd.
Kadimastem Ltd.
Kringle Pharma, Inc.
Lipopharma Therapeutics SL
Lpath, Inc.
MandalMed, Inc.
Mapreg S.A.S.
Mitsubishi Tanabe Pharma Corporation
Neuralstem, Inc.
Neuronax SAS
Omeros Corporation
PharmatrophiX, Inc.
Pharmicell Co., Ltd.
Q Therapeutics, Inc.
Quark Pharmaceuticals, Inc.
Remedy Pharmaceuticals, Inc.
RhinoCyte, Inc.
SanBio, Inc.
Sirnaomics, Inc.
StemCells, Inc.
Stemedica Cell Technologies, Inc.
TissueGene, Inc.
Vertex Pharmaceuticals Incorporated
Vicore Pharma AB
Spinal Cord Injury - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(buspirone + levodopa + carbidopa) - Drug Profile
ACTX-08 - Drug Profile
Antibody to Inhibit RGM for Spinal Cord Injury - Drug Profile
AP-325 - Drug Profile
AST-OPC-1 - Drug Profile
Astrostem - Drug Profile
AX-007 - Drug Profile
BA-277 - Drug Profile
BA-434 - Drug Profile
C-21 - Drug Profile
Cell Therapy for Spinal Cord Injury - Drug Profile
Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury - Drug Profile
Cerecellgram-Spine - Drug Profile
CHEC-7 - Drug Profile
CHEC-9 - Drug Profile
chondroitinase ABC nanosphere - Drug Profile
cimaglermin alfa - Drug Profile
CLR-01 - Drug Profile
CM-101 - Drug Profile
Drug for Spinal Cord Injury - Drug Profile
Enzyme to Inhibit Chondroitin Sulfate Proteoglycan for Spinal Cord Injury and Brain Injury - Drug Profile
FIB-117 - Drug Profile
glyburide - Drug Profile
GM-603 - Drug Profile
HBN-1 - Drug Profile
HC-016 - Drug Profile
HuCNS-SC - Drug Profile
ICCN-100 - Drug Profile
IMS-001 - Drug Profile
IMS-002 - Drug Profile
interferon beta-1a - Drug Profile
KP-100IT - Drug Profile
LM11A-31 - Drug Profile
LPA-181 - Drug Profile
Lpathomab - Drug Profile
MAP-4343 - Drug Profile
MultiStem - Drug Profile
NCP-01 - Drug Profile
Neural Stem Cells - Drug Profile
neurovitas - Drug Profile
NgR(310)ecto-Fc - Drug Profile
NRP-2945 - Drug Profile
NSI-566 - Drug Profile
NX-210 - Drug Profile
Oligonucleotide for Central Nervous System and Metabolic Disorders - Drug Profile
Peptide to Inhibit Ephrin-A for ALS and Acute Spinal Cord Injury - Drug Profile
Peptides for Central Nervous System and Musculoskeletal Disorders - Drug Profile
pregabalin ER - Drug Profile
PT-00114 - Drug Profile
Q-Cells - Drug Profile
Recombinant Protein for Spinal Cord Injury - Drug Profile
SB-618 - Drug Profile
SB-623 - Drug Profile
SC-0806 - Drug Profile
siRNA for CNS Disorders - Drug Profile
Small Molecule to Antagonize GPR17 for Central Nervous System Disorders - Drug Profile
Small Molecules for Spinal Cord Injury - Drug Profile
Stem Cell Therapy for Acute Spinal Cord Injury - Drug Profile
Stem Cell Therapy for CNS Disorders - Drug Profile
Stem Cell Therapy for Neurodegenerative Disorders - Drug Profile
Stem Cell Therapy for Spinal Cord Injury - Drug Profile
Stem Cell Therapy for Spinal Cord Injury - Drug Profile
Stem Cell Therapy Program for Neurodegenerative Diseases - Drug Profile
STP-805 - Drug Profile
SUN-13837 - Drug Profile
Synthetic Peptide for Spinal Cord Injuries - Drug Profile
Synthetic Peptides to Activate SDF-1 Alpha for CNS Disorders and Infectious Disease - Drug Profile
Tenascin-C Fragments for Spinal Cord Injury - Drug Profile
TG-N - Drug Profile
UH-0113 - Drug Profile
UH-0213 - Drug Profile
VX-210 - Drug Profile
Spinal Cord Injury - Recent Pipeline Updates
Spinal Cord Injury - Dormant Projects
Spinal Cord Injury - Discontinued Products
Spinal Cord Injury - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Spinal Cord Injury, H1 2015
Number of Products under Development for Spinal Cord Injury - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2015
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Spinal Cord Injury - Pipeline by Acorda Therapeutics, Inc., H1 2015
Spinal Cord Injury - Pipeline by Asubio Pharma Co., Ltd., H1 2015
Spinal Cord Injury - Pipeline by Athersys, Inc., H1 2015
Spinal Cord Injury - Pipeline by Axerion Therapeutics, Inc., H1 2015
Spinal Cord Injury - Pipeline by BioArctic Neuroscience AB, H1 2015
Spinal Cord Injury - Pipeline by Faron Pharmaceuticals Oy, H1 2015
Spinal Cord Injury - Pipeline by FirstString Research, Inc., H1 2015
Spinal Cord Injury - Pipeline by Genervon Biopharmaceuticals, LLC, H1 2015
Spinal Cord Injury - Pipeline by Grupo Ferrer Internacional, S.A., H1 2015
Spinal Cord Injury - Pipeline by Hemostemix Ltd, H1 2015
Spinal Cord Injury - Pipeline by Histocell S.L., H1 2015
Spinal Cord Injury - Pipeline by Intellipharmaceutics International Inc., H1 2015
Spinal Cord Injury - Pipeline by K-Stemcell Co., Ltd., H1 2015
Spinal Cord Injury - Pipeline by Kadimastem Ltd., H1 2015
Spinal Cord Injury - Pipeline by Kringle Pharma, Inc., H1 2015
Spinal Cord Injury - Pipeline by Lipopharma Therapeutics SL, H1 2015
Spinal Cord Injury - Pipeline by Lpath, Inc., H1 2015
Spinal Cord Injury - Pipeline by MandalMed, Inc., H1 2015
Spinal Cord Injury - Pipeline by Mapreg S.A.S., H1 2015
Spinal Cord Injury - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015
Spinal Cord Injury - Pipeline by Neuralstem, Inc., H1 2015
Spinal Cord Injury - Pipeline by Neuronax SAS, H1 2015
Spinal Cord Injury - Pipeline by Omeros Corporation, H1 2015
Spinal Cord Injury - Pipeline by PharmatrophiX, Inc., H1 2015
Spinal Cord Injury - Pipeline by Pharmicell Co., Ltd., H1 2015
Spinal Cord Injury - Pipeline by Q Therapeutics, Inc., H1 2015
Spinal Cord Injury - Pipeline by Quark Pharmaceuticals, Inc., H1 2015
Spinal Cord Injury - Pipeline by Remedy Pharmaceuticals, Inc., H1 2015
Spinal Cord Injury - Pipeline by RhinoCyte, Inc., H1 2015
Spinal Cord Injury - Pipeline by SanBio, Inc., H1 2015
Spinal Cord Injury - Pipeline by Sirnaomics, Inc., H1 2015
Spinal Cord Injury - Pipeline by StemCells, Inc., H1 2015
Spinal Cord Injury - Pipeline by Stemedica Cell Technologies, Inc., H1 2015
Spinal Cord Injury - Pipeline by TissueGene, Inc., H1 2015
Spinal Cord Injury - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2015
Spinal Cord Injury - Pipeline by Vicore Pharma AB, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Spinal Cord Injury Therapeutics - Recent Pipeline Updates, H1 2015
Spinal Cord Injury - Dormant Projects, H1 2015
Spinal Cord Injury - Dormant Projects (Contd..1), H1 2015
Spinal Cord Injury - Dormant Projects (Contd..2), H1 2015
Spinal Cord Injury - Dormant Projects (Contd..3), H1 2015
Spinal Cord Injury - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Spinal Cord Injury, H1 2015
Number of Products under Development for Spinal Cord Injury - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report